The progress in the development of DPI technology has boosted the use of sensitive drug molecules for lung diseases. However, delivery of these molecules from conventional DPI to the active site still poses a challenge with respect to deposition efficiency in the lung. At same time, serious systemic side effects of drugs have become a cause for concern. The developed budesonide loaded biopolymer based controlled release DPI had shown maximum in vitro lung deposition with least toxicity. The subject of present study, lactose-free budesonide loaded biopolymer based DPI, further corroborates the great potential of antiasthmatic drugs. This technology is expected to revolutionize the approaches towards enhanced therapeutic delivery of prospective drugs. 1. Introduction Corticosteroids have been found to be very effective for the control of mortality rate and approved as a maintenance therapy in asthmatic patients [1, 2]. Budesonide, a corticosteroid used in the first line therapy for coronary obstructive pulmonary disease (COPD), is available in the market as a conventional dry powder inhale (DPI). The optimum dose for budesonide is ranging between 200？μg and 800？μg. This is a potent nonhalogenated corticosteroid having maximum glucocorticoids receptor activity. The hepatic first pass metabolism of budesonide is approximately 90% which is the main reason for its low oral bioavailability of 6–11% having half-life 2-3？h [3]. The high doses of corticosteroids produce serious side effects upon long-term administration. There is need for controlled release budesonide DPI which could be administered through pulmonary route. Such a formulation could reduce the systemic side effects by achieving high local concentration in the lung and improve the patient compliance [4]. Pulmonary drug delivery system is explored as one of the alternative drug delivery systems due to higher surface area (100–140？m2), high permeation of lung, avoidance of hepatic first pass metabolism, and noninvasive route for drug administration [5, 6]. It was found to be the most efficient route for treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and now it is being explored for systemic administration of various categories of drug [7]. Drugs used for cancer, diabetes, and migraine could be efficiently administered by this route. Furthermore peptides, proteins, and genes can be administered through this route as these are stable in the dry form [8]. Conventionally dry powder inhalers (DPIs) are prepared by micronization methods which are often blends of fine drug
References
[1]
A. H. Morice, S. Peterson, O. Beckman, and D. Osmanliev, “Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma,” International Journal of Clinical Practice, vol. 61, no. 11, pp. 1874–1883, 2007.
[2]
S. L？helm？, M. Kirjavainen, M. Kela et al., “Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method,” British Journal of Clinical Pharmacology, vol. 59, no. 2, pp. 167–173, 2005.
[3]
N. A. Hanania, “The impact of inhaled corticosteroid and long-acting β-agonist combination therapy on outcomes in COPD,” Pulmonary Pharmacology and Therapeutics, vol. 21, no. 3, pp. 540–550, 2008.
[4]
S. R. Naikwade, A. N. Bajaj, P. Gurav, M. M. Gatne, and P. Singh Soni, “Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study,” AAPS PharmSciTech, vol. 10, no. 3, pp. 993–1012, 2009.
[5]
W. Yang, J. I. Peters, and R. O. Williams III, “Inhaled nanoparticles—a current review,” International Journal of Pharmaceutics, vol. 356, no. 1-2, pp. 239–247, 2008.
[6]
J. Fu, J. Fiegel, E. Krauland, and J. Hanes, “New polymeric carriers for controlled drug delivery following inhalation or injection,” Biomaterials, vol. 23, no. 22, pp. 4425–4433, 2002.
[7]
T. Sebti, G. Pilcer, B. Van Gansbeke et al., “Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 64, no. 1, pp. 26–32, 2006.
[8]
G. Pilcer, F. Vanderbist, and K. Amighi, “Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery,” International Journal of Pharmaceutics, vol. 365, no. 1-2, pp. 162–169, 2009.
[9]
C. Kumaresan, N. Subramanian, M. Gover Antoniraj, and K. Ruckmani, “Dry powder inhaler—formulation aspects,” Pharma Times, vol. 44, no. 10, pp. 14–18, 2012.
[10]
G. Saint-Lorant, P. Leterme, A. Gayot, and M. P. Flament, “Influence of carrier on the performance of dry powder inhalers,” International Journal of Pharmaceutics, vol. 334, no. 1-2, pp. 85–91, 2007.
[11]
H. Steckel and N. Bolzen, “Alternative sugars as potential carriers for dry powder inhalations,” International Journal of Pharmaceutics, vol. 270, no. 1-2, pp. 297–306, 2004.
[12]
W. S. Cheow, S. Li, and K. Hadinoto, “Spray drying formulation of hollow spherical aggregates of silica nanoparticles by experimental design,” Chemical Engineering Research and Design, vol. 88, no. 5-6, pp. 673–685, 2010.
[13]
N. El-Gendy, E. M. Gorman, E. J. Munson, and C. Berkland, “Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution,” Journal of Pharmaceutical Sciences, vol. 98, no. 8, pp. 2731–2746, 2009.
[14]
F. J. Ahmad, G. Mittal, G. K. Jain, G. Malhotra, R. K. Khar, and A. Bhatnagar, “Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 71, no. 2, pp. 282–291, 2009.
[15]
J. C. Sung, B. L. Pulliam, and D. A. Edwards, “Nanoparticles for drug delivery to the lungs,” Trends in Biotechnology, vol. 25, no. 12, pp. 563–570, 2007.
[16]
H. W. Frijlink and A. H. de Boer, “Dry powder inhalers for pulmonary drug delivery,” Expert Opinion on Drug Delivery, vol. 1, no. 1, pp. 67–86, 2004.
[17]
A. J. Hickey, H. M. Mansour, M. J. Telko et al., “Physical characterization of component particles included in dry powder inhalers—I. Strategy review and static characteristics,” Journal of Pharmaceutical Sciences, vol. 96, no. 5, pp. 1282–1301, 2007.
[18]
S. Divey, C. U. Yurteri, R. A. Grable, and M. K. Mazumder, “Effect of Charge on the deposition of electrostatically charged inhalable aerosol in lung model,” Journal of the Arkansas Academy of Science, vol. 56, pp. 146–152, 2002.
[19]
M. J. Telko, J. Kujanp？？, and A. J. Hickey, “Investigation of triboelectric charging in dry powder inhalers using electrical low pressure impactor (ELPI？),” International Journal of Pharmaceutics, vol. 336, no. 2, pp. 352–360, 2007.
[20]
S. Alipour, H. Montaseri, and M. Tafaghodi, “Preparation and characterization of biodegradable paclitaxel loaded alginate microparticles for pulmonary delivery,” Colloids and Surfaces B: Biointerfaces, vol. 81, no. 2, pp. 521–529, 2010.
[21]
S. De and D. Robinson, “Polymer relationships during preparation of chitosan-alginate and poly-l-lysine-alginate nanospheres,” Journal of Controlled Release, vol. 89, no. 1, pp. 101–112, 2003.
[22]
B. C. Lehtovaara, M. S. Verma, and F. X. Gu, “Synthesis of curdlan-graft-poly(ethylene glycol) and formulation of doxorubicin-loaded core-shell nanoparticles,” Journal of Bioactive and Compatible Polymers, vol. 27, no. 1, pp. 3–17, 2012.
[23]
Y. J. Son and H. S. Yoo, “PH-responsive microspheres encapsulated with iron oxide nanoaggregates for gastrointestinal delivery,” Journal of Bioactive and Compatible Polymers, vol. 27, no. 1, pp. 54–66, 2012.
[24]
U. H. Park, E. J. Lee, J. N. Knowles, and H. W. Kim, “Preparation of in situ hardening composite microcarrier: calcium phosphate cement combined with alginate for bone regeneration,” Journal of Biomaterials Applications, vol. 28, pp. 1079–1084, 2014.
[25]
B. Witold, M. Kucharska, T. Ciach, L. Koperski, Z. Jastrz？bski, and M. Sza？wiński, “Bone regeneration potential of the new chitosan-based alloplastic biomaterial,” Journal of Biomaterials Applications, vol. 28, pp. 1060–1068, 2014.
[26]
J. Malakar and A. K. Nayak, “Formulation and statistical optimization of multiple-unit ibuprofen-loaded buoyant system using 23-factorial design,” Chemical Engineering Research and Design, vol. 90, no. 11, pp. 1834–1846, 2012.
[27]
M. Rajaonarivony, C. Vauthier, G. Couarraze, F. Puisieux, and P. Couvreur, “Development of a new drug carrier made from alginate,” Journal of Pharmaceutical Sciences, vol. 82, no. 9, pp. 912–917, 1993.
[28]
K. Kristó, J. Bajdik, and K. Pintye-Hódi, “Optimization of the formulation of solid multiparticulate dosage forms containing pancreatin,” Chemical Engineering Research and Design, vol. 88, no. 8, pp. 1033–1036, 2010.
[29]
K. Gilani, A. R. Najafabadi, M. Darabi, M. Barghi, and M. Rafiee-Tehrani, “Influence of formulation variables and inhalation device on the deposition profiles of cromolyn sodium dry powder aerosols,” Daru, vol. 12, no. 3, pp. 123–130, 2004.
[30]
K. Iida, Y. Hayakawa, H. Okamoto, K. Danjo, and H. Leuenberger, “Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier,” Chemical and Pharmaceutical Bulletin, vol. 49, no. 10, pp. 1326–1330, 2001.
[31]
R. S. Dhumal, S. V. Biradar, A. R. Paradkar, and P. York, “Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery,” International Journal of Pharmaceutics, vol. 368, no. 1-2, pp. 129–137, 2009.
[32]
A. Abbas, M. Srour, P. Tang, H. Chiou, H.-K. Chan, and J. A. Romagnoli, “Sonocrystallisation of sodium chloride particles for inhalation,” Chemical Engineering Science, vol. 62, no. 9, pp. 2445–2453, 2007.
[33]
R. C. Nagarwal, R. Kumar, and J. K. Pandit, “Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye,” European Journal of Pharmaceutical Sciences, vol. 47, no. 4, pp. 678–685, 2012.
[34]
K. M？bus, J. Siepmann, and R. Bodmeier, “Zinc-alginate microparticles for controlled pulmonary delivery of proteins prepared by spray-drying,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 81, no. 1, pp. 121–130, 2012.
[35]
S. Patil, A. Pawar, and S. K. Sahoo, “Effect of additives on the physicochemical and drug release properties of pioglitazone hydrochloride spherical agglomerates,” Tropical Journal of Pharmaceutical Research, vol. 11, no. 1, pp. 18–27, 2012.
[36]
M. Simonoska Crcarevska, M. Glavas Dodov, and K. Goracinova, “Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 68, no. 3, pp. 565–578, 2008.
[37]
R. K. Das, N. Kasoju, and U. Bora, “Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 6, no. 1, pp. e153–e160, 2010.
[38]
F. Andrade, F. Goycoolea, D. A. Chiappetta, J. das Neves, A. Sosnik, and B. Sarmento, “Chitosan-grafted copolymers and chitosan-ligand conjugates as matrices for pulmonary drug delivery,” International Journal of Carbohydrate Chemistry, vol. 2011, Article ID 865704, 14 pages, 2011.
[39]
B. Chellampillai and A. P. Pawar, “Andrographolide, a novel bioactive phytoconstituent encapsulated in sustained release biodegradable nanoparticles,” International Journal of Nanotechnology, vol. 8, no. 8-9, pp. 764–778, 2011.
[40]
L. F. Zhang, D. J. Yang, H. C. Chen et al., “An ionically crosslinked hydrogel containing vancomycin coating on a porous scaffold for drug delivery and cell culture,” International Journal of Pharmaceutics, vol. 353, no. 1-2, pp. 74–87, 2008.
[41]
M. S. Hassan and R. Lau, “Inhalation performance of pollen-shape carrier in dry powder formulation: effect of size and surface morphology,” International Journal of Pharmaceutics, vol. 413, no. 1-2, pp. 93–102, 2011.
[42]
M. J. Telko and A. J. Hickey, “Dry powder inhaler formulation,” Respiratory Care, vol. 50, no. 9, pp. 1209–1227, 2005.
[43]
S. P. Newman, D. Pavia, F. Moren, N. F. Sheahan, and S. W. Clarke, “Deposition of pressurised aerosols in the human respiratory tract,” Thorax, vol. 36, no. 1, pp. 52–55, 1981.
[44]
X. Kou, L. W. Chan, H. Steckel, and P. W. S. Heng, “Physico-chemical aspects of lactose for inhalation,” Advanced Drug Delivery Reviews, vol. 64, no. 3, pp. 220–232, 2012.
[45]
A. Saigal, W. K. Ng, R. B. H. Tan, and S. Y. Chan, “Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension,” International Journal of Pharmaceutics, vol. 450, no. 1-2, pp. 114–122, 2013.
[46]
O. Harush-Frenkel, M. Bivas-Benita, T. Nassar et al., “A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery,” Toxicology and Applied Pharmacology, vol. 246, no. 1-2, pp. 83–90, 2010.
